The somatostatin analogs drug class accounted for the highest market share in 2018.

The acromegaly and gigantism are GH-related diseases. Gigantism occurs in children while acromegaly disease occurs in adults. This report provides an analysis of the market classified on the basis of drug class, GH receptor antagonists, somatostatin analogs, recombinant human IGF-1, dopamine agonists. On the basis of region, North America, Asia Pacific, Europe, Latin America and Middle East & Africa are covered.

One of the major factors driving the development of the market for acromegaly and gigantism drugs until 2025 will be the existence of a strong pipeline. Scientists focus on starting acromegaly and gigantism pipeline particles and most of these particles are in the development stage of Phase III. A massive number of particles available in the pipeline result in enhanced use of acromegaly and gigantism drugs. By concentrating more on drug development, various companies are trying to meet the medical requirements for this disorder.

Novartis long-acting release pasireotide (LAR) and Chiasma octreotide capsules are in the phase III development stage for acromegaly treatment. They are aimed at people with acromegaly who are insufficiently treated by somatostatin analogs and Ipsen with the monotherapy of pegvisomant and lanreotide autogel. This in turn leads to a strong pipe line for the therapy of acromegaly and gigantism. Regardless of market insights of acromegaly and gigantic drugs, this market will record a CAGR of approximately 3 percent over the forecast period.

The somatostatin analogs drug class accounted for the highest market share. The study will also provide a precise forecast of the contribution of the different drug class segments to the growth of the market size of acromegaly and gigantism drugs. Due to the low rate of success of acromegaly surgical procedures, demand for semi-surgical options and the popularity of pharmacological treatments for acromegaly treatment are growing on a continuous basis. That’s one of the main trends that will enhance the growth of the market size and share of acromegaly and gigantism drugs. Only four of the 310 subjects allowed to treat with trans-sphenoidal procedure were noted to have been healed.  In addition, there was also an impairment of post-operative anterior pituitary cortisol in about 10 subjects. Due to the lack of qualified surgeons and pituitary surgical locations, the preference of drug treatments for curing the disease will continue to rise

The drugs market for acromegaly and gigantism is relatively fragmented with firms focusing on new medicines development. This acromegaly and gigantism drug industry analysis report is intended to help clients identify potential opportunities for growth and design innovative techniques to improve their market position by offering a thorough analysis of the competitive environment of the market and with info on the services offered by the manufacturers.

To withstand a position in the market, established players are taking strategies footsteps such as develop cost efficient drugs, investment in R&D, entering into agreements etc. The key global players of Acromegaly and Gigantism Drugs market are Novartis AG, Ipsen, Pfizer Inc., Chiasma, Inc., Ionis Pharmaceuticals Inc., Crinetics Pharmaceuticals, and Midatech Pharma Plc.